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Abstract
Understanding the transition of bacterial species from commensal to pathogen,
or vice versa, is a key application of evolutionary theory to preventative medicine.
This requires working knowledge of the molecular interaction between hosts and
bacteria, ecological interactions among microbes, spatial variation in bacterial
prevalence or host life history, and evolution in response to these factors. How-
ever, there are very few systems for which such broad datasets are available. One
exception is the gram-negative bacterium, Helicobacter pylori, which infects
upwards of 50% of the global human population. This bacterium is associated
with a wide breadth of human gastrointestinal disease, including numerous can-
cers, inflammatory disorders, and pathogenic infections, but is also known to
confer fitness benefits to its host both indirectly, through interactions with other
pathogens, and directly. Outstanding questions are therefore why, when, and
how this bacterium transitions along the parasitism–mutualism continuum. We
examine known virulence factors, genetic predispositions of the host, and envi-
ronmental contributors that impact progression of clinical disease and help
define geographical trends in disease incidence. We also highlight the complexity
of the interaction and discuss future therapeutic strategies for disease manage-
ment and public health in light of the longstanding evolutionary history between
the bacterium and its human host.
Introduction
The human-specific bacterium, Helicobacter pylori, infects
an estimated 50% of the world’s adult population, with the
highest prevalence in industrially underdeveloped areas
(Kauser et al. 2004). Genetic evidence suggests H. pylori as
one of the oldest and most common occupants of the
human gut microbiome, arriving before the migration out
of Eastern Africa over 60 000 years ago (Linz et al. 2007;
Ahmed et al. 2009; Plottel and Blaser 2011). Despite this
long association, substantial histologic, epidemiologic, and
experimental data suggest H. pylori is a causative agent of
life-threatening diseases such as gastric adenocarcinoma
(GAC) and gastric MALT Lymphoma, as well as their pre-
cursory gastric lesions such as chronic gastritis, gastric atro-
phy, intestinal metaplasia, and dysplasia (Crew and Neugut
2006). A long-term observational study (mean follow-up:
7.8 years) of 1246 H. pylori -positive and 280 H. pylori
-negative patients, including those with active duodenal
ulcers, active gastric ulcers, gastric hyperplastic polyps, or
nonulcer dyspepsia, found 36 cases (2.9%) of gastric cancer
in the H. pylori -positive cohort with no cases of gastric
cancer in the H. pylori -negative cohort (Uemura et al.
2001). Despite well-documented carcinogenic properties,
H. pylori infection is pervasive both through time and
across space. It is therefore possible that the bacterium con-
fers a benefit to its host under some circumstances and is
therefore maintained in the human population. Some evi-
dence for such a benefit exists (Table 1); it has been sug-
gested that H. pylori confers protection against tuberculosis
(TB) through induction of antagonistic interferons for the
causative agent, Mycobacterium tuberculosis, and that it
plays a role in reducing the risk of esophageal adenocarci-
noma (EAC), gastroesophageal reflux disease, stroke, lung
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cancer, asthma, allergies, and irritable bowel disease (Blaser
1999; Ahmed et al. 2009; Luther et al. 2010; Perry et al.
2010; Plottel and Blaser 2011; Walker and Talley 2014).
Antibacterial activity against other virulent bacterial spe-
cies has also been documented, showing a preventative
effect against diarrheal diseases and an augmented enteral
and systemic response to Vibrio cholerae, the causative
agent of the disease cholera (Blaser and Berg 2001; Cohen
et al. 2012; but see Clemens et al. 1995; Shahinian et al.
2000).
A better understanding of the factors that move this
potential pathogen along the parasitism–mutualism con-
tinuum is key for effective detection, management, and dis-
ease prevention (Fig. 1). This is especially true given the
emerging interest in microbiome health and the developing
datasets aiming to uncover the composition of ‘healthy’
human microbiota across the population (B€ackhed et al.
2012). Our understanding of this bacterium continues to
be confounded by uncertainties surrounding mode of
transmission, environmental influences, effects of host
genotype, and complex ecological interactions within the
microbiome (e.g. Rolig et al. 2013). In this review, we aim
to explore the interactions between H. pylori bacteria and
their human hosts by considering trends in geographic var-
iation, association with disease, genes underlying virulence,
interactions with other microbes, and the influence of host
immune response. We then highlight future directions for
management of H. pylori -associated disease as it relates to
preventative public health.
Factors known to contribute to disease
development
As one of few organisms to be classified as a ‘group 1 (defi-
nite) carcinogen’ by the International Agency for Research
on Cancer, colonization by H. pylori has a major etiological
association with increased risk of several gastric disorders
including gastric cancer, which accounts for 10% of all can-
cers worldwide and over 700 000 deaths every year (Ahmed
et al. 2009; Kodaman et al. 2014). Only a small subset of
infections (<1%) develops into gastric cancer due to,
among other things, the range of alternate factors contrib-
uting to severity of infection (Fig. 1; Kodaman et al. 2014),
some of which include bacterial polymorphism, genetic
predisposition, diet, and socioeconomic-related living con-
ditions. In this section, we will explore what is currently
known about the many interacting factors underlying
H. pylori -associated disease.
Table 1. Examples of current evidence in support of both harmful and
beneficial effects correlated with Helicobacter pylori infection.
Effect of infection
Affect on
health Citation
Increased prevalence of
gastric cancer
() Uemura et al. (2001),
Kodaman et al. (2014)
Increased risk of infection
with Vibrio cholera, and risk
of progressing to severe
cholera
()
()
Shahinian et al. (2000),
Clemens et al. (1995)
Increased prevalence of
peptic ulcers
() Maeda et al. (1998)
Chronic and acute gastritis () Graham et al. (2004)
Suppression of bacteria
causing tuberculosis
(+) Perry et al. (2010)
Reduced risk of eczema (+) Amberbir et al. (2011)
Reduced risk of
gastroesophogeal reflux
disease
(+) Sonnenberg et al. (2010)*
Protection against
diarrheal diseases
(+) Cohen et al. (2012)
Reduced risk of
esophageal cancer
(+) Islami and Kamangar (2008)
Reduction of asthma
and allergy
(+) Chen and Blaser (2007)
Reduced risk of irritable
bowel disease
(+) Luther et al. (2010)
*But see Qian et al. (2011).
Pathogen Commensal Mutualist
Bacterial adherence to gastric epithelium
Expression of VacA and Cag A virulence factors
Proinflammatory interleukin-8 (IL-8) gene expression 
Allopatry of host and bacterium
High dietary salt intake
Greater bact
Co-infe  Vibrio cholerae 
Increased horizontal transmission
1
Bact  
Pr alizing urease
Down re st nitric oxide pr n
Helical cell shape
Evasion of host immune defense
10,11
12
2,3
Presence of Cag A gene
ted immunity
Sympatry of host and bacterium
16
4
5
5
6
8
9
7
9
13
14
17
Figure 1 Schematic summarizing the key genetic, ecological, and evo-
lutionary factors known to influence the transition of Helicobacter pylori
along the parasitism–mutualism continuum. Factors known to increase
potential pathogenicity are in red, those that are involved in coloniza-
tion and survival in the human host, but which have no direct evidence
of conferring either cost or benefit to the host are in black, and factors
that are thought to be associated with conferred benefits to the host
(either directly or indirectly) are in green. Further factors that are pre-
dicted from theory but which have not been examined empirically are
included in italics. Details of each association are discussed within the
main text. References: (1) Oleastro and Menard (2013); (2) Censini
et al. (1996); (3) Maeda et al. (1998); (4) Persson et al. (2011); (5) Kod-
aman et al. (2014); (6) Gaddy et al. (2013); (7) Atherton et al. (1996);
(8) Leon-Barua et al. (2006); (9) Anderson and May (1982); (10) Eaton
et al. (1992); (11) Ottemann and Lowenthal (2002); (12) Tsuda et al.
(1994); (13) Gobert et al. (2001); (14) Bonis et al. (2010); (15) Salama
et al. (2013); (16) Chen and Blaser (2007); (17) Arnold et al. (2011).
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Virulence factors
The majority of H. pylori infections are benign, and the
development of clinical disease depends on a variety of fac-
tors such as adherence of the bacterial cells to the gastric
epithelium (Oleastro and Menard 2013) as well as some
not yet well-understood genetic, epigenetic, and environ-
mental factors (Wroblewski et al. 2010), but primarily
depends on the presence of two different genes, the cyto-
toxin-associated gene A (CagA) and the vacuolating cyto-
toxin (VacA) (Ahmed et al. 2009). Motility of H. pylori
cells in the stomach lining is common, but several different
outer membrane proteins facilitate the binding of bacterial
cells to gastric epithelial surfaces (Algood and Cover 2006).
This binding has been linked to evasion from the host
immune system and long-term persistence, as well as
increased delivery of the CagA oncoprotein into gastric
cells, all of which are linked to disease (Oleastro and
Menard 2013). Virulence factors such as flagella and stom-
ach acid-neutralizing urease are also common attributes of
all H. pylori strains. Knockout mutants of the flagellar or
urease genes are unable to colonize gnotobiotic piglets or
other animal models (Eaton et al. 1992; Tsuda et al. 1994;
Covacci et al. 1999; Ottemann and Lowenthal 2002; Al-
good and Cover 2006).
The bacterial polymorphisms considered to be the most
important contributors to H. pylori cytotoxicity and car-
cinogenicity are those found within the CagA gene of the
cag pathogenicity Island (CagPAI), a set of genes coding for
a type IV secretion system, and those influencing the activ-
ity of VacA genes, a secreted protein toxin responsible for
gastric epithelial erosion (Censini et al. 1996; Ahmed et al.
2009; Duncan et al. 2013). For example, activity of the
VacA gene was found in 16 of 24 (67%) patients with pep-
tic ulcers but in only 16 of 53 (30%) patients without
(Maeda et al. 1998). Although VacA is present across
H. pylori strains, it is estimated that only 50% of all western
strains secrete vacuolating cytotoxin (Figura et al. 1989),
one of the factors that leads to the observed lower rate of
clinical infection in western countries. This marker is there-
fore of little use for predicting pathogenicity of circulating
strains, as it seems to be the expression of the gene, rather
than any particular mutation, that is important in shaping
the outcome of disease. This also suggests the ease at which
this bacterium might be able to respond to the host
environment and alter its phenotype accordingly.
CagA is the gene most strongly associated with highly
carcinogenic strains (Bourzac and Guillemin 2005), and
the interplay between the CagA and VacA loci has proven
to be an important contributor to the development of gas-
tritis and GAC (Matos et al. 2013; Rahimian et al. 2014;
but see Xiang et al. 1995). CagA is thought to only be pres-
ent in approximately 60% of H. pylori strains and, unlike
VacA, is almost always expressed when present (Maeda
et al. 1998). Serum anti-CagA antibodies were found in
165 of 197 (84%) patients with duodenal cancer, but in
only 25 of 45 (56%) patients with functional dyspepsia.
This marker is therefore a useful candidate for monitoring
and predicting disease, although clearly the association is
not tight enough to be used in diagnosis. In this case, there-
fore, bacterial genetics plays a clear but not singular role in
pathogenicity. Opposed to the increased risk of gastric can-
cer, recent evidence and a meta-analysis of 19 different
studies suggest CagA-positive strains are also associated
with a decreased risk of EAC, asthma, and allergies (Islami
and Kamangar 2008; Chen and Blaser 2007; Pacifico et al.
2014). The potential protective effect of H. pylori against
asthma has also been experimentally confirmed in a mouse
model (Arnold et al. 2011). Again, this work highlights the
extreme difficulty associated with predicting the outcome
of disease in patients harboring H. pylori infection, given
the great variation and somewhat weak associations
observed.
H. pylori’s causative and protective roles with GAC and
EAC, respectively, are further evidenced by a marked
decline in the prevalence of both H. pylori and GAC in the
developed world, but a rise in EAC such that it now makes
up approximately half of all esophageal cancers in countries
such as the United States and the United Kingdom (Islami
and Kamangar 2008). This rise in EAC strongly correlates
to the disappearance of both H. pylori and peptic ulcers
from the developed world over the last several decades;
although risk factors such as alcohol consumption,
tobacco, and obesity need also be considered (Islami and
Kamangar 2008; Whiteman et al. 2008), as does the wide-
spread dissemination of antibiotics, whether for agricul-
tural or medicinal purposes, that contributes to the shifting
composition of the gut microbial community (Jernberg
et al. 2010; Zeissig and Blumberg 2014). It is theorized that
urease activity in H. pylori neutralizes the stomach’s acidity
and consequently protects against EAC by lowering the risk
of acid-reflux disease; but due to the complex nature of the
microbiome, further research is necessary to define the role
of H. pylori and differentiate it from simply a biomarker
for the decline of other beneficial microbial species.
Given the potential for harm, and the long evolutionary
association between H. pylori and its human host
population, we should expect mechanisms of both human
immune responses to the bacterium and of counter adapta-
tion by the bacterium to evade the host immune response.
Indeed, H. pylori is known to have several strategies to
avoid antigenic recognition through phase and surface
protein variation, and certain strains are also capable of
emulating host cells through the use of the surface proteins
pbgA and pbgB that bind plasminogen, thereby coating
themselves with this host protein and making them
© 2014 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd 8 (2015) 9–22 11
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undetectable as foreign agents (J€onsson et al. 2004; Algood
and Cover 2006). Other strategies for avoiding detection
involve the O-antigen of the H. pylori lipopolysaccharide
(LPS), a potent signaler of inflammatory response; the
majority of H. pylori tested worldwide have LPS that mimic
Lewis blood group antigens (Simoons-Smit et al. 1996;
Algood and Cover 2006). The LPS is a common pathogen-
associated molecular pattern (PAMP) and a major compo-
nent of the outer membrane of bacterial cells that can be
recognized by the innate immune system of hosts. Portions
of the LPS are highly conserved across H. pylori strains, but
there has also been good evidence for high levels of phase
variation of this antigen within patients (Appelmelk et al.
1998). Specifically in the Lipid A region, the portion of the
LPS recognized by host immune receptors, there is a large
amount of within-host variation presumably as a result of
its versatility in adapting to the specific host conditions
(Suarez and Peek 2014). The potential role of such within-
host variation in causing disease has yet to be tested.
The ability of H. pylori to evade detection and subse-
quent elimination by the host immune response (Salama
et al. 2013) likely contributes to its sustained occupation of
the human gut. The resistance of many H. pylori strains to
immunological elimination may be maintained by its high
recombination rate (rate at which recombination events
start at any particular nucleotide, r = 6.9 9 105) and
mutation rate (l = 4.1 9 105), for example relative to
E. coli (r = 7 9 1012; l = 3 9 1010) (Falush et al. 2001;
Kennemann et al. 2011). However, recent work examining
isolates collected from the same patients over time, as well
as individuals from the same families, suggests that substi-
tutions are three times more likely to have been introduced
by recombination than mutation (Morelli et al. 2010). This
work also demonstrates that while the introduction of
mutations is frequent, the rate of substitution over longer
time periods is many fold lower, in part due to purifying
selection acting on nonsynonymous mutations. Further-
more, while H. pylori is known to constitutively express the
mismatch repair pathway, it has a distinct response to
DNA damage. The most common bacterial response to
DNA damage is the SOS response, which typically includes
transcriptional induction of DNA repair systems and a
temporary halt to cell division. However, H. pylori lacks
this pathway and responds to stress by inducing natural
competence (i.e., the uptake of DNA from the environ-
ment; Dorer et al. 2010). This elevated recombination rate
increases H. pylori variability and potential for adaptation
to the host environment (Suerbaum and Josenhans 2007).
Isolates from unrelated host individuals are different
enough for H. pylori to be considered a ‘quasi-species’, the
majority of mutations occurring in the third base of
codons, therefore giving a diverse genetic fingerprint while
conserving 93% of genomic protein sequences between
strains (Covacci et al. 1999). Independent isolates often
vary from one another by 3–5% of base substitutions, even
in essential housekeeping genes, which is a level of variation
not often seen in other bacterial pathogens (Datta et al.
2003). Much of this genetic diversity could be expected
from the long evolutionary history of the association and
the high mutation rate, but given the rate of divergence
observed even across hosts from similar geographical loca-
tions, it is more likely that there exist many circulating
strains with slightly different phenotypes and/or that this
variation has great adaptive potential for the bacterial pop-
ulation. In particular, the known virulence-associated
genes, VacA and CagA, are more likely to contain nonsyn-
onymous variation, suggesting selection pressure on these
proteins to vary functionally and structurally to avoid rec-
ognition (Datta et al. 2003). Together, this high unex-
plained variation and somewhat weak association between
bacterial genome and disease suggest that although genetics
is likely to be a strong contributing factor to disease emer-
gence and progression, alternate factors such as the host
genotype, environment, or interactions within the microbi-
ome are also likely to play a key role.
Genetic predisposition of hosts
Addressing the host genetic component of clinical infection
must be performed in the context of geographical location,
socioeconomic environment, and cultural practices. A
prime example of epidemiological complexity in relation to
H. pylori is found in a study of three ancestrally, and
geographically, distinct communities in West Bengal: the
Oroan, the Santhal, and the ethnic Bengalis (Datta et al.
2003). The lineages of the Oroan (ethnically proto-Austra-
loid) and the Santhal (ethnically Dravidian) are ethnic
minorities representing 5% of the population with only
rare intermarriage with other ethnic groups, as evidenced
by distinct autosomal and mitochondrial DNA markers.
These communities are similar in socioeconomic status,
with relatively low levels of hygiene and sanitation, making
them good communities for studying H. pylori infection,
which is abundant. Despite cultural, geographical, and
genetic isolation, PCR analysis of CagA and VacA in
H. pylori from across the groups revealed that strains from
different ethnic groups share similar frequencies of chosen
genetic markers. This similarity, in conjunction with wide-
spread metronidazole resistance (an antibiotic used in
mainstream communities since the 1970s but not used by
the Oroan or Santhal), argues for close relatedness between
strains of H. pylori and recent transmission into and
between groups. Similar abundance of H. pylori infection
and of CagA+/VacA+ strains would be expected to
correspond to similar abundance of H. pylori -associated
gastrointestinal disease between groups. However, this was
12 © 2014 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd 8 (2015) 9–22
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not found to be the case. Although clinical infection is
common among ethnic Bengalis (representing the ethnic
majority and believed to have Indo-European ancestry), it
is virtually nonexistent in the cohorts from the two ethnic
minorities. This distinction suggests several different, but
not mutually exclusive, possibilities: [I] as host inflamma-
tory response to H. pylori varies with host genotype (Datta
et al. 2003), these genetically distinct host populations
could be differentially reactive to the same enteric patho-
gens; [II] subtle mutational differences, such as point
mutations undetected by the study, among strains might
play a significant role in determining expression and
potency of virulence genes; or [III] due to the predicted
positive correlation between transmission frequency and
virulence (Bremermann and Pickering 1983), it is possible
that larger communities with higher population density
facilitate higher transmission frequency and, in turn, select
for increased virulence (Anderson and May 1982),
although one argument against this theory includes high
incidence of gastric cancer in less dense rural populations
(Ma et al. 1998).
In the case of H. pylori, geographical differences in infec-
tion might be better explained by socioeconomic, genetic,
and cultural factors than by physical location, but multiple
uncontrolled variables make it impossible to attribute onset
of clinical infection to a single factor. Although the specific
case from communities in West Bengal cannot definitively
implicate ethnicity as a component of H. pylori infection,
another study found a fourfold higher bacterial coloniza-
tion rate among African-Americans compared to Cauca-
sians within the same community and socioeconomic class
(Malaty et al. 1999). This 12-year follow-up study of 212
children found 40% of the African-American cohort was
infected with H. pylori by age 7, compared to 11% of the
Caucasian cohort, with 50% of the Caucasian cohort elimi-
nating infections over the 12-year period, and only 4% of
African-Americans eliminating the bacteria from their mic-
robiota. Although the children in the study attended the
same schools, the researchers did not take into account
social behavior, customs, or dietary habits.
Current research on host polymorphisms in inflamma-
tory response genes supports the role of host genetics in
determining predisposition to gastric cancer (GC). Helicob-
acter pylori -induced GC is a product of a chronic inflam-
matory response, and differing host responses likely
determine the outcome of H. pylori infection. One meta-
analysis of 62 studies, conducted on a total of 24 577
patients with GC worldwide, including 9905 H. pylori
-positive patients and 14 672 H. pylori -negative patients,
uncovered a clear role for host genetics in the development
of GC (Persson et al. 2011). By studying single nucleotide
polymorphisms (SNPs) in the host interleukin (IL) genes,
inflammatory cytokines mediating gastric physiology and
pathophysiology, investigators were able to identify several
high-risk polymorphisms, one of the most significant being
a polymorphism in the proinflammatory interleukin-8 (IL-
8) gene (Persson et al. 2011). IL-8 transcription leads to
increased oxidative stress on the gastric mucosa, is pro-
duced as a response to H. pylori, and is upregulated by
CagA expression (Yamaoka et al. 1999a,b). Furthermore, a
genomewide association study (GWAS) in Japan identified
the prostate stem cell antigen (PSCA) gene, a glycosylphos-
phatidylinositol-anchored cell surface antigen, as a gastric
cancer-susceptibility gene, and the Mucin 1 (MUC1) gene,
a cell membrane bound mucin protein, as risk factors for
gastric cancer (Saeki et al. 2013). However, this latter study
did not explicitly test for an interaction between H. pylori
infection and the genes identified as risk factors.
To support the idea of host genome-by-bacterial genome
interaction in determining clinical infection, a recent study
run in Colombia concluded that differences in severity of
gastric lesions could be explained by coevolution between
human and H. pylori populations (Kodaman et al. 2014).
Host genetics in this region are shaped by migration and
mating among populations of European, African, and
Amerindian ancestry. Admixture analysis of high-density
human genotypic data revealed a predominantly African
ancestral cluster in the low-risk, coastal populations, with
similar proportions of Amerindian and European ancestry;
whereas the high-risk, mountain populations were pre-
dominantly Amerindian, with a significant proportion of
European ancestry and negligible African ancestry. Congru-
ously, all strains of H. pylori in this study also contained
the genetic signatures of European, African, and Amerin-
dian backgrounds. However, coastal isolates were predomi-
nantly African in ancestry, whereas mountain isolates were
predominantly European. The authors suggest the relatively
benign infections observed in coastal populations can be
attributed to the matching of predominantly African ances-
try of both host and bacteria. The more severe infections of
mountain populations are suggested to be a product of
mismatch between ancestrally Amerindian hosts with
European strains. In this case, the interaction effect was
found to be five times higher than the main effect of CagA
identity, leading the authors to theorize that higher bacte-
rial fitness (in terms of growth rate) in allopatric strains
could lead to a competitive advantage over the indigenous
strains. These findings are in accordance with evolutionary
theory, which predicts that chronic pathogens with vertical
transmission will become less virulent over time through
coevolution, and could help explain the ‘African Enigma,’
or the exceptionally low incidence of gastric cancer in
Africa despite very high rates of H. pylori infection (Hol-
combe 1992). Clinical infection and the shift to parasitism
by H. pylori might therefore primarily be a product of mis-
matched host and parasite genomes; however, further
© 2014 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd 8 (2015) 9–22 13
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research needs to be performed to determine whether this
is a localized phenomenon or applicable to all populations,
especially in light of gene flow among populations.
Dietary practices
Regional and cultural differences in dietary practices likely
contribute to both the rate of H. pylori infection and the
severity of infection. For example, one study performed in
Pune, India, identified lower socioeconomic status, meat
consumption, smoking, eating restaurant food, and drink-
ing nonfiltered or nonboiled water as risk factors for infec-
tion (Mhaskar et al. 2013). Additionally, meat/fish
consumption and family history of peptic ulcer disease
were found to be risk factors for peptic ulcer disease, while
parasite infection and chili pepper consumption were
indicative of protective effects. High-salt diets have recently
been found to exacerbate H. pylori infection by upregulat-
ing transcription of CagA and increasing the risk of GAC;
the same results were found for low-iron diets (Gaddy et al.
2013). However, as both meat/fish and high-salt diets have
also been associated with a wealth of other health risks that
decrease host fitness, it is unclear whether their effect on
H. pylori growth and virulence is direct or indirect.
One 15-year follow-up study of H. pylori-infected indi-
viduals found evidence that both garlic and vitamin intake
(of E, C, and selenium) were ineffective at preventing inci-
dence of gastric cancer, although there was some associa-
tion with decreased mortality (Ma et al. 2012), and there is
some evidence that diets high in fruits and vegetables can
decrease risk of H. pylori infection (Brown 1999). For
example, one recent study found diets of broccoli sprouts
rich in sulforaphane (a compound with powerful bacterici-
dal properties) were able reduce H. pylori colonization and
gastric inflammation relative to sulforaphane-poor alfalfa
sprouts; these effects are predicted to be both direct via an-
tibacterials and indirect through increased mammalian cy-
toprotective response (Yanaka et al. 2009). Additional
research has explored dietary supplementation and demon-
strated anti- H. pylori properties observed in vivo from
green tea, liquorice, and honey; red wine provided minor
symptomatic relief and use of propolis resulted in conflict-
ing results (Ayala et al. 2014). More research is now needed
not only on the combined effects of these supplements in
long-term maintenance of H. pylori infection but also in
determining the mechanistic link between diet and infec-
tion, as well as diet and progression of H. pylori -associated
disease. Elimination of nickel from the diet also increases
the success rate of H. pylori eradication when used in con-
junction with triple antibiotic therapy; eradication
increased from 12 of 26 individuals (standard diet) to 22 of
26 individuals (nickel free) (Campanale et al. 2014). The
authors attribute this to disruption of urease and
NiFe-hydrogenase, two critical nickel-containing enzymes
in H. pylori. In terms of additional environmental/behav-
ioral factors known to influence susceptibility, there is evi-
dence that use of well water, use of pit latrine, less frequent
boiling of drinking water, and infrequent hand wash prac-
tice after toilet use and before meals act as high-risk factors
for H. pylori infection, while several regionally specific
foods have also been found to be protective (Lee et al.
2012). These environmental/behavioral risk factors are not
surprising, as H. pylori is known to be transmitted through
oral–oral and fecal–oral routes.
Length of infection
Among the factors known to influence the transition from
H. pylori infection to progression of clinical disease is the
acquisition and elimination of the bacterium in early child-
hood and the length of infection (Pounder and Ng 1995;
Ma et al. 1998; Brown 1999). Incidence of gastric cancer
has been shown to be higher in areas where childhood
infection is common, while duodenal ulcers are a more
common outcome of adult onset infections (Brown 1999).
Trends in H. pylori infection are also associated with a
country’s relative stage of development. According to the
Human Development Index (HDI), the majority of chil-
dren from ‘underdeveloped’ or ‘developing’ countries
become infected during childhood and maintain chronic
infection throughout life (Brown 1999; Kusters et al. 2006).
One study from the Shandong Province in China found
that children ages 5–6 and adults have comparable rates of
infection at approximately 70% (Ma et al. 1998), implying
infection is maintained throughout life. In contrast, only a
minority of children from ‘developed’ countries becomes
infected, and infection frequency increases proportionally
with age (Pounder and Ng 1995; Kusters et al. 2006). A
Canadian review of H. pylori prevalence found that first
generation individuals who immigrated as adults
(>20 years of age) had a rate of infection, and a rate of gas-
tric cancer consistent with their country of origin, with an
odds ratio of 9.7 times that of second generation individu-
als. These results paralleled US studies (Jones et al. 2012).
As spontaneous elimination is uncommon, it is not sur-
prising that infection in immigrants reflects that of their
native country, but together, these results argue that trans-
mission dynamics are specific to the region in question.
Spontaneous elimination of H. pylori by the immune
system is more common in children but rarely observed in
adults (Kusters et al. 2006), only occurring in 0.1–1.1% of
infections annually (Pounder and Ng 1995; Brown 1999).
Therefore, early childhood infection typically results in an
extended length of infection and likely affords more oppor-
tunities for oncogenic mutations, although a defined role
for H. pylori in tumorigenesis is still actively debated, with
14 © 2014 The Authors. Evolutionary Applications published by John Wiley & Sons Ltd 8 (2015) 9–22
Helicobacter pylori: pathogen or commensal? Lin and Koskella
several studies supporting a range of theories. Two possible
pathways are suggested for gastric tumorigenesis: one
assigns carcinogenic activity to H. pylori itself, while the
other describes the establishment of a carcinogenic envi-
ronment due to long-term infection (Mobley et al. 2001).
Both mechanisms involve the initial complication of super-
ficial gastritis progressing into atrophic gastritis, which
eventually develops into intestinal metaplasia, a precursor
for gastric cancer. Other theories outline the exact mecha-
nism of tumor formation. For example, one model invokes
the recruitment of stem cells from the bone marrow
observed during H. pylori -mediated gastric inflammation
(Houghton et al. 2004), while another proposes that
chronic H. pylori -induced gastric inflammation makes the
niche inhabitable, eliminates H. pylori, and supports other
cancer-promoting microbial species (Plottel and Blaser
2011). This latter theory is contradicted by prevention of
gastric carcinoma from prophylactic eradication of
H. pylori after detection of early gastric cancer (Fukase
et al. 2008), but this discrepancy may be indicative of the
different modes of tumorigenesis that depend on cancer
type. Interestingly, there is currently a lack of evidence
showing any connection between immunodeficiency, such
as acquired immunodeficiency syndrome, and uncontrolla-
ble H. pylori infections, despite this being a common situa-
tion with other pathogens (Pounder and Ng 1995). This is
unsurprising in context of H. pylori’s ability to evade host
immune defenses and supports the theory that chronic
inflammatory response over a lifetime is mainly responsible
for promoting gastric cancer.
Transmission dynamics
As a bacterium detectable throughout the world, H. pylori
is capable of colonizing a wide spectrum of host gastroin-
testinal niches and microniches (Blaser and Atherton
2004). Studies on habits that contribute to transmission
have been inconsistent in their results and vary depending
on investigators and cohorts. Overall, proper nutrition is
associated with a decrease in transmission, while factors
associated with a lower socioeconomic status (i.e. inade-
quate sanitation, high-density living spaces, and contami-
nated food and water) and eating raw or uncooked
vegetables facilitate transmission (Brown 1999). Although
the exact mechanism of transmission is unknown, infection
is highly correlated to human crowding and poor sanita-
tion (Jones et al. 2012). Discrepancies in transmission
routes are attributed to the difficulty in culturing oral, gas-
tric, and fecal isolates and the resulting lack of data, but the
predominant theory involves direct human-to-human
transmission with evidence for both oral–oral and fecal–
oral transmission (Brown 1999). One study of 289 adults
and 98 children in a Chinese village with an exceptionally
high risk of stomach cancer revealed an infection rate of
89% for children with at least one infected parent and only
22% for children with no infected parents (Ma et al. 1998),
suggesting a primarily vertical mode of transmission. Some
H. pylori infections are conserved to the point where chil-
dren have similar strains as their parents and will maintain
those strains after starting their own family; oddly enough,
however, husbands and wives have been shown to not typi-
cally exchange strains (Covacci et al. 1999). Familial/verti-
cal transmission of parasites is predicted to select for
reduced virulence over time (Anderson and May 1982),
which may be reflected in the relative tolerance to H. pylori
by most human hosts. However, the occurrence of horizon-
tal transmission (especially given the increased movement
of recent humans) may well negate any such selective pres-
sures.
Socioeconomic factors play a distinct role in transmis-
sion due to differences in waste management, hygiene, and
the likelihood of practices such as premastication by par-
ents and sharing of eating utensils such as chopsticks
(Dowsett and Kowolik 2003). Helicobacter pylori has been
detected in oral cavities, fecal samples, houseflies, and
under fingernails, and it is suggested that each of these are
possible routes of transmission, although the likelihood of
each differs regionally (Dowsett and Kowolik 2003; Kusters
et al. 2006). The body of research on whether oral H. pylori
is viable as a gastric pathogen offers conflicting evidence
and obscures the oral–oral route of transmission. However,
there is a possibility that nonviable oral H. pylori can still
participate in horizontal gene transfer with existing gastric
colonies, diversifying the infection, especially when the
high recombination frequency among strains is taken into
account (Kennemann et al. 2011). Horizontal transmission
is likely to increase in unsanitary, highly crowded environ-
ments, making multiple infection and recombination
among strains more common in dense populations (Jones
et al. 2012; Kodaman et al. 2014). Increased horizontal
transmission may help explain why certain regions exhibit
high rates of gastric cancer despite evidence of predomi-
nantly vertical transmission for the system as a whole.
Although the association between CagA status and bacte-
rial density in vivo has had conflicting support, CagA-posi-
tive strains are known to trigger high levels of interleukin
production, whereas CagA-negative strains trigger little to
no interleukin production (Atherton et al. 1996; Yamaoka
et al. 1999a,b). Bacterial density has been shown to be
directly related to severity of disease, with higher density in
duodenal ulcers than in gastritis (Atherton et al. 1996), and
it has been suggested that the increased inflammation asso-
ciated with CagA-positive strains may also be associated
with higher transmission rates between hosts (Blaser 1997).
The fact that CagA frequency varies geographically, with
more CagA-positive strains in East Asia (making up
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approximately 90% of all isolates [Saribasak et al. 2004;
Duncan et al. 2013]) than in western countries, suggests
the possibility of a fitness trade-off preventing CagA-posi-
tive status from spreading to fixation globally. One possi-
bility is that the increased transmissibility is a function of
increased growth rate within the host and that this growth
rate explains both increased spread and increased harm to
the host. Classic evolutionary theory on the virulence-
transmission trade-off suggests that while increased within-
host growth rate should increase bacterial fitness through
transmission success, there is also a cost in terms of host
death rate (Anderson and May 1982; Bremermann and Pic-
kering 1983; May and Anderson 1983; Ewald 1987; Frank
1996). As such, while CagA-positive strains may benefit
from easier communicability, their increased virulence is
likely to decrease the time frame during which they are
communicable by the host; CagA-negative strains may ben-
efit from a longer host life and therefore a longer period of
communicability. However, the direct application of such
classic evolutionary theory should be made with caution
given the difference in generation time between the host
and the bacterium. For example, it is unclear whether the
shortened life span of hosts is sufficient to impose mean-
ingful selection pressure on the pathogen population.
Indeed, many of the diseases associated with H. pylori
infection occur later in life. This potentially relaxes selec-
tion on the bacterial population, but also alters the
response to selection of hosts; the more likely onset of
H. pylori -associated cancers in postreproductive hosts
could mean little to no response to selection in the human
population (Greaves 2007). Further theoretical work and
system-specific modeling could help inform predictions
regarding the response of both bacteria and host popula-
tion to selection mediated by the other.
Transmission of H. pylori is also influenced by interac-
tions within the other bacteria, both pathogens and com-
mensals. Contaminated water and poor community
hygiene, both indicators of socioeconomic status, are
known risk factors for H. pylori, as well as V. cholerae.
Interactions between these gastrointestinal pathogens
increase the severity of the disease and consequently alter
transmission dynamics. In one study of 75 H. pylori -posi-
tive patients from Peru, 35 of which had cholera-induced
dehydration and 40 of which had no history of cholera, the
patients with cholera were found to have significantly more
chronic atrophic gastritis (45.7% vs 12.5%; P = 0.002) and
intestinal metaplasia (37.1% vs 2.5%; P < 0.01) in the gas-
tric body than those without cholera (Leon-Barua et al.
2006). Both chronic atrophic gastritis and intestinal meta-
plasia result in inflammation of the stomach and increase
the risk of gastric adenocarcinoma (Stemmermann 1994;
Giannakis et al. 2008). The observed inflammation aligns
with the findings that orally administered V. cholerae
vaccines signal the recruitment of antibody secreting cells
to the gastric mucosa only in patients with active H. pylori
infections (Mattsson et al. 1998). In individuals lacking
vibriocidal immunity, H. pylori infection was associated
with a significant increase in risk of life-threatening cholera
(Clemens et al. 1995). Vibrio cholerae-induced diarrhea
eases H. pylori transmission through the fecal route, which
minimizes the cost of increased host inflammatory
response. Data such as these highlight one of the many
unknown interactions H. pylori potentially has with other
bacterial species, pathogenic or not, that contribute to both
transmission and virulence.
Geographic variation of infection
The long coevolutionary history between humans and
H. pylori is intimate enough for H. pylori genotyping to
distinguish between closely related human groups. As a
symbiotic accompaniment of human migration out of
Africa, DNA analysis of H. pylori can accurately reflect
population movement and gene flow between locally dis-
tinct populations; this is in part due to its primarily vertical
transmission, which creates a global genetic structure paral-
leling that of humans (Wirth et al. 2004). The use of trans-
criptomics to examine global gene expression across
isolates has further underpinned evidence of phylogeo-
graphic variation among strains (Sheh et al. 2013). By
coculturing clinical isolates with gastric epithelial cells,
transcriptional profiles could be compared across strains
from regions with low and high risks of GC, uncovering
clear transcriptional differences among genes associated
with motility and pathogenicity, including upregulation of
CagA and VacA in ancestrally European strains. The full
explanation of why CagA-positive/negative strains vary
geographically is still unknown. Korea and Japan have the
highest rates of GC worldwide, which is in part due to a
high incidence of H. pylori infections relative to other
developed countries in North America and Europe (Saeki
et al. 2013). Interestingly, Japan has a high rate of GC (age-
standardized incidence rate of 62.7/100 000), but a lower
rate of H. pylori seroprevalence (39.3%) than other coun-
tries such as Bangladesh (92%) and India (79%), which
exhibit much lower rates of GC with 1.6/100 000 and 5.7/
100 000, respectively. These geographic differences are
likely explained by the interaction between H. pylori and
host genetics, as well as environmental influences. In agree-
ment with this expectation, one study uncovered two high-
risk host genotypes and one potentially protective genotype
within the Japanese population; 95% of the population was
found to have one of the two risk genotypes and 56% were
found to have both, while there was an exceptionally low
frequency of the protective genotype (Saeki et al. 2013).
These risk phenotypes coincide with findings that most
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Japanese strains of H. pylori produce both CagA and VacA
(Maeda et al. 1998). There is a clear role of susceptible host
genotypes in shaping the observed trends in geographic
variation of infection outcome, but the ability to generalize
such a pattern beyond this population is yet to be deter-
mined.
Geographic trends in disease incidence are well matched
by geographic trends in H. pylori virulence genes. For
example, a study of 335 H. pylori DNA samples from 8
countries worldwide (Spain, Peru, South Africa, England,
Ireland, Japan, Costa Rica, and India) found considerable
variation in the organization of the cag-PAI (Kauser et al.
2004). PCR analysis revealed a high prevalence of gene
rearrangements within the CagPAI, more so than any other
region on the chromosome. The CagPAI was disrupted in
the majority of patient isolates throughout the world, with
57.1% of Japanese isolates exhibiting the highest occur-
rence of intact CagPAI followed by Peruvian (18.6%) and
Indian (12%) isolates (Kauser et al. 2004). One Turkish
study of 65 H. pylori -positive patients (22 with gastritis, 33
with peptic ulcer disease, and 10 with gastric cancer) dis-
covered a higher frequency of CagA-negative isolates that
more closely resembled Western strains, which helps
explain Turkey’s low rates of GC relative to countries such
as Japan and Korea (Saribasak et al. 2004). In agreement
with H. pylori’s high rate of rearrangement in the CagPAI,
CagA-positive and CagA-negative strains with the same
genetic fingerprint are often cultured from the same indi-
vidual (Morales-Espinosa et al. 1999). This suggests that
during prolonged infection, CagA-positive strains can
excise the CagPAI to create isogenic CagA-negative strains
that may remain a minority, disappear, or become the
majority. Because CagA status is used frequently as a
genetic marker, this within-host variation could contribute
to the geographic variation in CagA-positive/negative
strains; diet, the microbiome, and host genetic factors
could play an important role in determining frequency of
CagA conversion.
Conclusions/future directions
Clinical disease caused by H. pylori is predicted to stem
from biochemical changes in stomach physiology, such as
changes in pH, nutrient supply, and physical alteration;
however, symptoms for disease are only present in 20% of
infected hosts (Blaser 1999). Disease therefore appears to
be an exception to the rule, and severity appears to be
directly related to the combination of duration of infection
and intensity of the host’s inflammatory response (corre-
lated with bacterial density). A multitude of factors, such as
CagA status, dietary habits, and host susceptibility, are
known to trigger the inflammatory response, but as a gen-
eralized statement heightened inflammation increases risk
of disease. With current research focusing on factors that
exacerbate the inflammatory response, researchers are now
working toward a better understanding of the transition of
H. pylori along the parasite–mutualist continuum (Fig. 1).
This understanding will increase success in eradication for
high-risk populations, while potentially maintaining the
bacteria in low-risk populations, or specifically targeting
more pathogenic strains. Given the recent discussion sur-
rounding the active eradication of H. pylori from the
human population (Lee et al. 2013), it is more important
than ever to critically evaluate its role within the microbi-
ome. The long history of coevolution between this bacteria
and its human host (Kodaman et al. 2014) suggests it is
particularly pertinent to address why these bacteria have
had such a successful history and whether any benefits con-
ferred in the past have now been ameliorated (Blaser 1999).
From a public health perspective, eradication is effective
and realistic for the resources available; this is likely the
best strategy for high-risk populations where gastric disease
is common. The shortcomings of standard H. pylori eradi-
cation therapy are in the antibiotics it requires. ‘Triple ther-
apy’ of a proton pump inhibitor (PPI) in combination with
two antibiotics, commonly clarithromycin and metronida-
zole, is standard for H. pylori eradication. Reported eradi-
cation rates in the early 90s were 95%, whereas a 2007
meta-analysis of over 53 000 patients showed an eradica-
tion rate of <80% (Tong et al. 2007; Dajani et al. 2013).
The decreasing efficacy of antibiotic therapy makes it unre-
alistic to expect success with population-wide eradication.
New research on quadruple therapy (one PPI and three
antibiotics) had a 95.8% success rate with successful eradi-
cation in 23 of 24 patients (Thiraworawong et al. 2014).
Based on trends with triple therapy, this arms race has a
predictable outcome, and it is likely only a matter of time
before resistance evolves to quadruple therapy. With cur-
rent methods, the amount of antibiotics needed for a
strictly eradication-based regimen would only promote
widespread antibiotic resistance, which is already consid-
ered a threat to global security by WHO. According to the
CDC’s 2013 Threat Report on antimicrobial resistance in
the United States, two million people are infected by
antibiotic resistant organisms each year with at least 23 000
people dying from these infections (CDC Threat Report
2013). The losing battle with antibiotic resistance in tradi-
tionally antibiotic-susceptible organisms drives the need
for novel strategies in approaching infectious agents such
as H. pylori. Movement must now be made to decrease
dependence on antibiotics as the sole therapeutic strategy
for all microbial infections.
No currently available, alternative therapies rival the
efficacy of antibiotics, but current research on managing
microbiomes and the protective effects from pre- and pro-
biotic consumption continues to offer promise (Tong et al.
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2007). Probiotics, defined as microorganisms with poten-
tially beneficial health effects, such as Lactobacilli, secrete
antimicrobial compounds that have been shown to inhibit
or kill H. pylori in vitro. For example, supplementing stan-
dard triple therapy with Lactobacilli increased treatment
efficacy from 71 to 81%, and Bifidobacterium infantis sup-
plements to the standard therapy increased eradication
from 68.9 to 83% while reducing antibiotic-related side
effects (Lesbros-Pantoflickova et al. 2007; Tong et al. 2007;
Dajani et al. 2013). One review found 7 of 9 human studies
showed a decrease in H. pylori density and improvement in
H. pylori gastritis with probiotic administration (Lesbros-
Pantoflickova et al. 2007). Another study found Lactobacil-
lus plantarum secretes factors that modulate inflammation
during H. pylori infection (Thiraworawong et al. 2014).
The preliminary research on probiotic treatments has pro-
vided inconsistent results with varying degrees of efficacy,
and no study has been able to demonstrate H. pylori eradi-
cation in vivo from probiotics alone (Lesbros-Pantoflickova
et al. 2007; Dajani et al. 2013). However, the studies dem-
onstrating reduction of colony density and decreases in
gastric inflammation (Pacifico et al. 2014) are indicative of
the potential for alternative treatments through gut
microbiome management as opposed to strict eradication.
It is also unknown how these results reflect ‘normal’ levels
of dietary probiotic intake, and more research needs to be
conducted on long-term dietary supplementation of probi-
otics through fermented foods. Work on mouse models is
beginning to uncover complex interactions between
H. pylori and other bacterial species commonly found in
the human gut, such as Clostridium difficile (Rolig et al.
2013), suggesting an intriguing link between dysbiosis and
H. pylori -mediated disease.
The research presented by Kodaman et al. (2014) on
human and H. pylori coevolution introduces the possibility
of managing H. pylori -induced gastric disease by ‘match-
ing’ a host and bacterial strain based on common ancestral
association (i.e., artificially recreating the low-risk, genetic
association between host and strain such as that observed
in the case of the ‘African Enigma’). If more compatible
strains are also able to outcompete less compatible strains
within the host, such treatment could offer sustained health
benefits. However, to do this successfully, further informa-
tion about the interaction and the particular regions of the
host and bacterial genome for which ancestry is most
important would need to be obtained. Furthermore, to bet-
ter understand the mutualistic role of H. pylori in low-risk,
H. pylori -positive cohorts, more research needs to be per-
formed to quantify the health benefits (Table 1). It is possi-
ble that H. pylori constitutes a valuable, albeit mismanaged,
member of the healthy gut microbiome and requires a spe-
cific host environment to confer benefit to the host. Any
considerations of implementing a treatment regimen that
uses H. pylori as a probiotic immediately encounters sev-
eral major obstacles: [I] individualizing treatments for each
patient would likely require extensive on-site technology
(this complication is particularly difficult as the observed
benefits of H. pylori colonization are most valuable in low-
socioeconomic areas where medical resources are already
scarce); [II] The high rates of recombination and natural
competence observed in H. pylori would defy any attempt
at maintaining a defined host–pathogen association, espe-
cially in ethnically diverse areas; [III] The mechanism for
the development of carcinogenic activity by H. pylori is still
largely uncontrollable and unpredictable. Until this mecha-
nism is better understood, it would be unwise and unethi-
cal to propagate a known carcinogen. However, the use of
recombinant genomics increases the possibility of
‘designer’ probiotics made from incorporating protective
gene sequences from H. pylori into avirulent species to
remove the risk involved with H. pylori infection.
Other alternatives for H. pylori therapy include vac-
cines. As a low-cost and easily distributed prophylaxis,
vaccines would be ideal and have even had success in
animal models through memory T-cell activation. How-
ever, high mutation rate and other immunomodulatory
mechanisms used by H. pylori to persist in the gastric
niche make it more resistant to immune response (Al-
good and Cover 2006; Ayala et al. 2014). Intragastric
ultraviolet light phototherapy has also been effective with
a >97% reduction in bacterial load of the antrum,
although urea test results indicated bacteria tend to
repopulate within a few days after illumination (Ayala
et al. 2014). Bacteriophage therapy also holds potential
to be a viable alternative to antibiotic treatment due to
the specificity of many phages on their hosts compared
to the wide-ranging effects of antibiotics. A recent study
characterizing an H. pylori -specific bacteriophage
KHP30 revealed a broad host range (KHP30 was able to
infect 28 of 44 different H. pylori strains), stability over
a wide range of pH from 2.5 to 10 (with the pH of the
solution unchanged suggesting stability of the phage),
and pseudolysogenic activity based on episomal and
plasmid DNA that does not incorporate into the genome
(Uchiyama et al. 2013). As the first H. pylori -specific
phage to be characterized, the broad host range and pH
stability are hopeful attributes for bacteriophage therapy,
and further research needs to be performed to under-
stand the capacity for bacterial modification/elimination
in vivo. Finally, new developments in fecal transplants
have also been shown to restore intestinal microbiotal
balance in patients with Clostridium dificile infection,
with  90% of patients showing recovery (Bakken et al.
2011). This method has not yet been extended to
H. pylori infection, but based on evidence of competitive
inhibition through probiotics, there is potential that the
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same principles will apply. These prospects provide
exciting new directions for preventative health care but
would require careful monitoring and should be
approached with caution due to the extensively docu-
mented carcinogenic properties of H. pylori.
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